Guaifenesin and Dextromethorphan Hydrobromide Tablets 400 +20 mg

Guaifenesin and Dextromethorphan Hydrobromide by

Drug Labeling and Warnings

Guaifenesin and Dextromethorphan Hydrobromide by is a Otc medication manufactured, distributed, or labeled by APNAR PHARMA LP, Apnar Pharma Private Limited, APNAR PHARMA LLP. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE- guaifenesin and dextromethorphan hydrobromide tablet 
APNAR PHARMA LP

----------

Guaifenesin and Dextromethorphan Hydrobromide Tablets 400 +20 mg

Caution: do not use if imprinted seal under cap is broken or missing

Drug Facts

Active Ingredients (per tablet)

Guaifenesin USP...................................... 400 mg

Dextromethorphan Hydrobromide USP...... 20 mg

Purpose

Expectorant

Cough suppressant

Uses:

  • Temporarily relieves cough due to minor throat and bronchial irritation as may occur with the common cold
  • Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus
  • Helps make coughs more productive.

WARNINGS

Do not use

  • if you are now taking a prescription Monoamine Oxidase Inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before using this product.

Ask a doctor before use if you have

  • Persistent or chronic cough, such as occurs with smoking, asthma, chronic bronchitis or emphysema
  • Cough accompanied by excessive phegm (mucus)

Stop use and ask a doctor if

  • Symptons are accompanied by fever, rash or persistent headache
  • cough persists for more than 1 week or tends to recur
  • A persistent cough may be a sign of a serious condition

If pregnant or breast-feeding, ask a healthcare professional before use.

Keep out of reach of children

In case of overdose, get medical help or contact poison control center immediately

Directions

  • Adults and children 12 years of age and over: take 1 tablet every 4 hours as needed
  • Children 6 to 12 years of age: take 1/2 tablet every 4 hours as needed
  • Children under 6 years of age: consult a doctor.

Do not exceed 6 doses in 24 hour period or as directed by a doctor

Other Information

  • store at 15°-30°C (59°-86°F)

Inactive Ingredients

Microcrystalline cellulose, Croscarmellose sodium, Povidone, silicon dioxide, magnesium stearate

Questions or concerns?

  • 1-855-642-2594

Distributed by:

APNAR PHARMA LP

CHINO, CA, 91710

Rev.: 04/2022

APNAR PHARMA LP

NDC: 24689-123-01

Guaifenesin and Dextromethorphan Hydrobromide Tablets 400 + 20mg- 20s tablets

Guaifenesin and Hbr tablets 400+20mg- 20s tablets

APNAR PHARMA LP

NDC: 24689-123-02

Guaifenesin and Dextromethorphan Hydrobromide Tablets 400 + 20mg- 500s tablets

Guaifenesin and Hbr tablets 400+20mg- 500s tablets

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE 
guaifenesin and dextromethorphan hydrobromide tablet
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC: 24689-123
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) GUAIFENESIN400 mg
DEXTROMETHORPHAN HYDROBROMIDE (UNII: 9D2RTI9KYH) (DEXTROMETHORPHAN - UNII:7355X3ROTS) DEXTROMETHORPHAN HYDROBROMIDE20 mg
Inactive Ingredients
Ingredient NameStrength
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
POVIDONE K30 (UNII: U725QWY32X)  
WATER (UNII: 059QF0KO0R)  
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
Product Characteristics
ColorwhiteScore2 pieces
ShapeCAPSULESize18mm
FlavorImprint Code LT13
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC: 24689-123-0120 in 1 BOTTLE; Type 0: Not a Combination Product12/30/2022
2NDC: 24689-123-02500 in 1 BOTTLE; Type 0: Not a Combination Product12/30/2022
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC Monograph DrugM01312/30/202201/22/2025
Labeler - APNAR PHARMA LP (079568229)
Establishment
NameAddressID/FEIBusiness Operations
APNAR PHARMA LLP118530917pack(24689-123) , label(24689-123)
Establishment
NameAddressID/FEIBusiness Operations
Apnar Pharma Private Limited876730408analysis(24689-123) , manufacture(24689-123)

Revised: 12/2025
 

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.